alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['C481F'],"[{'ncitCode': 'C81934', 'drugName': 'Ibrutinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 533, 'code': 'CLLSLL', 'color': 'LimeGreen', 'name': 'Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'mainType': {'id': None, 'name': 'Mature B-Cell Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'MBN', 'level': 5, 'tumorForm': 'LIQUID'}",[],"['26182309', '27282255']",[],"Ibrutinib is an irreversible small-molecule tyrosine kinase inhibitor of BTK that is NCCN-listed and FDA-approved for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with or without 17p deletion. In a study of 308 patients with CLL who enrolled in four sequential clinical trials of ibrutinib, one patient had a C481F mutation at disease progression with a variant allele frequency of 84% (PMID: 27282255, 26182309)."
